Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Author:
Affiliation:
1. Resverlogix Corp. Calgary Alberta Canada
Funder
Resverlogix Corp.
Publisher
Wiley
Subject
Drug Discovery,Pharmacology,Molecular Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/med.21730
Reference233 articles.
1. Biological and molecular effects of bromodomain and extra‐terminal (BET) inhibitorsJQ1,IBET‐151, andIBET‐762 inOSCCcells
2. Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
3. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
4. BET bromodomain proteins regulate enhancer function during adipogenesis
5. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Cited by 79 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An updated patent review of BRD4 degraders;Expert Opinion on Therapeutic Patents;2024-09-04
2. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma;Cells;2024-08-28
3. Uterine fibroids: current research on novel drug targets and innovative therapeutic strategies;Expert Opinion on Therapeutic Targets;2024-08-02
4. A Novel BD2-Selective Inhibitor of BRDs Mitigates ROS Production and OA Pathogenesis;Antioxidants;2024-08-02
5. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury;Biomedicine & Pharmacotherapy;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3